Table 2.

CI for HNSCC cell lines after treatment with cetuximab plus 2.5 µM MK2206 for 72h.

Cell line	Condition	CI
SC263-S	2.5 µM MK2206 + 25 nM cetuximab	0.775
	2.5 µM MK2206 + 50 nM cetuximab	0.707
SCC22b-S	2.5 µM MK2206 + 25 nM cetuximab	0.757
	2.5 µM MK2206 + 50 nM cetuximab	0.730
SC263-R	2.5 µM MK2206 + 25 nM cetuximab	0.783
	2.5 µM MK2206 + 50 nM cetuximab	0.728
SCC22b-R	2.5 µM MK2206 + 25 nM cetuximab	0.937
	2.5 µM MK2206 + 50 nM cetuximab	0.917

CI < 0.800, CI = 1.000 ± 0.200, and CI > 1.200 indicate synergism, additivity or antagonism, respectively. CI < 0.800 are indicated in bold. Suffix -S: cetuximab sensitive cell line and suffix -R: acquired cetuximab resistant cell line.